Skip to Content
Learn about Adcetris a treatment of Hodgkin Lymphoma

Cisplatin Pregnancy and Breastfeeding Warnings

Cisplatin is also known as: Platinol, Platinol-AQ

Medically reviewed on Sep 24, 2018

Cisplatin Pregnancy Warnings

Use is contraindicated.

AU TGA pregnancy category: D
US FDA pregnancy category: D

-This drug can harm a developing fetus.
-This drug should not be used during pregnancy unless the clinician considers the risk to be clinically justified.
-If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.
-Genetic consultation is recommended if the patient wishes to have children after ending therapy with this drug.
-Since this drug may cause irreversible infertility, it is recommended that men who wish to become fathers in the future ask for advice regarding cryoconservation of their sperm prior to treatment.
-Pregnancy should be avoided during therapy with this drug and for a minimum of 6 months after therapy has ended; this applies to patients of both sexes.

Animal studies have revealed evidence of embryotoxicity and teratogenicity. There are no controlled data in human pregnancy.

AU TGA pregnancy category D: Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details.

US FDA pregnancy category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Cisplatin Breastfeeding Warnings

Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy, especially alkylating agents such as this drug. Excretion of platinum into milk occurs, but results are inconsistent. The exact form and toxicity of platinum excreted into breastmilk are also not known. The nursing infant would receive any platinum compounds orally rather than IV and oral absorption of oral platinum compounds by infants is not known.

Use is contraindicated.

Excreted into human milk: Yes

-This drug can harm a nursing infant.
-Chemotherapy may adversely affect the normal microbiome and chemical makeup of breastmilk.
-Women who receive chemotherapy during pregnancy are more likely to have difficulty nursing their infant.

See references

References for pregnancy information

  1. "Product Information. Cisplatin (CISplatin)." Teva SICOR Pharmaceuticals Inc, Irvine, CA.

References for breastfeeding information

  1. "Product Information. Cisplatin (CISplatin)." Teva SICOR Pharmaceuticals Inc, Irvine, CA.
  2. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.